Multi-field innovation achievements enter the outbreak period! Zhongjin raised the target price twice to boost GRAND PHARMA (00512) to challenge a market value of 30 billion.

Recently, the stock price of the leading innovative pharmaceutical company GRAND PHARMA (00512) in the Hong Kong stock market has continued to rise, achieving a strong 4-day consecutive increase. The intraday increase today exceeded 7%, and the weekly increase exceeded 20%. The short-term stock price has doubled. Behind this strong performance is the company's consecutive innovative achievements in multiple fields: the companys global innovative drug STC3141 for the treatment of sepsis in phase II clinical trials has reached the clinical endpoint, and the application for TLX591, a novel radiopharmaceutical drug in the field of nuclear medicine therapy for cancer, to join the international multicenter phase III clinical trial has been accepted by the National Medical Products Administration. In addition, GRAND PHARMA has received another endorsement from the well-known investment bank CICC, raising its target price by over 10% to 8 Hong Kong dollars for the second time. With its leading global research and development capabilities, GRAND PHARMA has continuously achieved innovative breakthroughs in multiple business areas such as nuclear medicine for cancer therapy, respiratory and critical care, and ophthalmology in recent years. The innovative pipeline is accelerating to fruition, and it is expected to continue leading the industry and break out of an independent market trend, initiating a new round of value reassessment. In the field of nuclear medicine therapy for cancer, as one of the only four companies globally to achieve the commercialization of innovative nuclear medicine, GRAND PHARMA's nuclear medicine sector has become the core engine for explosive performance. In 2024, the revenue from the nuclear medicine therapy for cancer sector reached approximately 589 million Hong Kong dollars, an increase of nearly 177% year-on-year. The core product of this sector, Yttrium-90 (90Y) microsphere injection (Y90) under the brand name Yttriga, has become the core driver of revenue growth, contributing nearly 500 million Hong Kong dollars in revenue with a growth rate of over 140% year-on-year for two consecutive years. In terms of its nuclear medicine innovative pipeline, GRAND PHARMA has reserved 15 innovative products in the development and registration stage focusing on the integrated treatment concept of cancer therapy. These products cover 5 radiopharmaceutical isotopes including Gallium-68, Lutetium-177, Iodine-131, Yttrium-90, and Zirconium-89, targeting 7 types of cancer including liver, prostate, kidney, and brain cancer. The products encompass both diagnostic and therapeutic capabilities, offering patients multiple treatment options for different indications and a globally leading integrated anti-cancer therapy solution. Currently, GRAND PHARMA has 4 innovative nuclear medicine drugs in the registration stage for clinical research, with 3 of them entering phase III clinical trials. GRAND PHARMA is currently the enterprise with the highest number of diagnostic and therapeutic category innovative nuclear medicine drugs entering phase III clinical research in China and one of the innovative drug companies with the most abundant product pipeline and integrated diagnosis and treatment layout in the field of nuclear medicine therapy for cancer globally. It is truly a global leader in the nuclear medicine field. In terms of industrial layout, GRAND PHARMA has achieved a comprehensive layout in various aspects including research and development, production, sales, and regulatory qualifications, establishing a complete industrial chain. In addition, the global research and production base for radiopharmaceuticals in Wenjiang, Chengdu, has completed the main structure topping-out earlier and successfully passed the on-site inspection of the radiation safety permit organized by the Ministry of Ecology and Environment in March of this year. It is expected that a total investment of approximately 3 billion yuan will be made in this nuclear medicine base, and it is expected to gradually complete the FDA clinical application for products from the end of this year to 2026. The base is positioned as a global highland for the industrialization of innovative nuclear medicine, focusing on core areas such as isotope process development and preparation, nuclear medicine coupling technology, and automated labeling technology, covering a one-stop full lifecycle management including early research in nuclear medicine, process development, quality control, non-clinical research, intelligent production, and precise distribution. It aims to establish a world-class research and development, production quality, and operation system. In addition, the base will build the world's first zero radiation intelligent nuclear medicine factory through full-process intelligent monitoring and closed-loop management. It is currently the most extensive in terms of variety of isotopes and automation level of intelligent factories internationally. At the same time, the base will also jointly establish a global nuclear medicine research center network with the company's research center in Boston, USA, and GRAND PHARMA-Shandong University Radiopharmaceutical Research Institute, and rely on technological innovation, global talent, and intelligent manufacturing to solidify GRAND PHARMA's leading position in the field of nuclear medicine. Breakthrough in critical care: STC3141 may fill the clinical treatment gap worth billions In the respiratory and critical care sector, GRAND PHARMA's globally innovative drug STC3141, independently developed with global intellectual property rights, has recently reached the clinical endpoint in phase II clinical trials for the treatment of sepsis in China. Data from Wise Guy Reports shows that the global market for sepsis treatment drugs was $12.54 billion in 2024, and is expected to reach $19.37 billion by 2032, with a compound annual growth rate of 5.58%. STC3141 is expected to break the long-term lack of targeted drugs in the field of sepsis and become a revolutionary therapy with pioneering significance in the field of critical care, accurately addressing and meeting the urgent clinical treatment needs. In the future, GRAND PHARMA will actively engage in in-depth communication with the regulatory authorities, apply for breakthrough therapy designation, and allow STC3141 to benefit a wide range of sepsis patients as soon as possible, filling the clinical treatment gap. It is worth noting that in addition to STC3141, GRAND PHARMA has multiple products with significant commercial potential in the respiratory and critical care sector. In the field of rhinitis, GRAND PHARMA has become one of the companies with the most comprehensive product pipeline for treating allergic rhinitis in China and has a domestically leading nasal spray formulation platform. The company's matrix of "high barrier generic drugs + innovative drugs" inhalation products is gradually taking shape. Once innovative nasal spray combination products like Ryaltris are launched in the future, they will provide more high-value core increments for the company's rhinitis sector. In the field of asthma, the most prevalent chronic respiratory disease in the respiratory field, GRAND PHARMA's products are also distinctive and innovative. With two globally innovative commercialized products, they have established a solid presence in the market. In the field of ophthalmology, GRAND PHARMA has promising products such as innovative eye drops that have received favorable evaluation in clinical studies and are expected to bring new opportunities for growth in this sector. Overall, GRAND PHARMA's continuous innovative achievements in various sectors demonstrate its strong research and development capabilities, market competitiveness, and potential for future growth. The company is poised to lead the industry, drive technological innovation, and provide high-quality healthcare solutions to meet the needs of patients globally.Take the prescription drugs Entorun and Enmingrun as examples, these two products can effectively improve clinical symptoms and lung function in patients with moderate to severe asthma, significantly reduce the risk of acute attacks, and have broad market prospects. These two products have been included in the latest national medical insurance list and have quickly gained traction in the market.GRAND PHARMA's innovative layout in the respiratory and critical care fields has not only enhanced the competitiveness of its product pipeline, but also demonstrated the company's strong global innovation research and development capabilities through the smooth progress of the global multicenter clinical trial of STC3141. Differentiated innovation opens up a market space of billions, GRAND PHARMA maintains a leading position in the ophthalmology field. In recent years, influenced by factors such as aging population, increasing demand for eye care due to the widespread use of electronic products, the demand for treatment of ophthalmic diseases has been expanding. Correspondingly, the market for innovative ophthalmic drugs is continuously growing, leading to the emergence of a group of ophthalmic drug research and production enterprises, among which GRAND PHARMA is one. GRAND PHARMA has always regarded the ophthalmology field as one of its important strategic development directions, focusing on ophthalmic drug innovation, persisting in professional development, and continuously enhancing its industry status and market competitiveness. In more than ten years of deep cultivation, the company has attracted and nurtured a group of professionals with both clinical and marketing experience in the ophthalmology field, established a customer-centric, academically-led specialized marketing team and formed long-term stable partnerships with large pharmaceutical distribution enterprises and chain pharmacies to establish a nationwide marketing network. Currently, GRAND PHARMA has built a "professional, full range, multi-variety" innovative drug product system in the ophthalmology field, with a reserve of multiple global innovative products for treating "myopia," "dry eye syndrome," "pinguecula," "postoperative ophthalmic anti-inflammatory analgesics," "Demodex blepharitis," and "Meibomian gland dysfunction caused by Demodex," and has made significant R&D progress. In the next three years, multiple innovative products are expected to be approved for marketing. GRAND PHARMA's research and development progress in the ophthalmology field not only reflects its technological innovation capabilities but also demonstrates its deep understanding of patient needs. By developing innovative products targeting unmet clinical needs, the company is gradually building a diversified, high barrier ophthalmic product portfolio. Looking at the layout of GRAND PHARMA in various sectors, it can be seen that the company's success is inseparable from its persistence in technological innovation and accurate grasp of market demand. Against the background of rapid development in the global pharmaceutical industry, the company's core drive lies in differentiated innovation and an international perspective. It is making forward-looking strategic layouts in multiple fields, providing security for the company's long-term development, while the continuous landing of innovative product pipelines injects strong momentum, continuously driving the value of GRAND PHARMA upward - the company is reshaping the global competitiveness of Chinese innovative drugs with a "grand" pace of research and development.